10 results on '"Pakiz, Maja"'
Search Results
2. Incidence of positive peritoneal cytology in patients with endometrial carcinoma after hysteroscopy vs. dilatation and curettage
- Author
-
Dovnik Andraz, Crnobrnja Bojana, Zegura Branka, Takac Iztok, and Pakiz Maja
- Subjects
endometrial carcinoma ,peritoneal cytology ,figo staging ,hysteroscopy ,dilatation and curettage ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
The aim of the study was to compare the frequency of positive peritoneal washings in endometrial cancer patients after either hysteroscopy (HSC) or dilatation and curettage (D&C).
- Published
- 2016
- Full Text
- View/download PDF
3. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma,
- Author
-
Rodolakis, Alexandros, primary, Scambia, Giovanni, additional, Planchamp, François, additional, Acien, Maribel, additional, Di Spiezio Sardo, Attilio, additional, Farrugia, Martin, additional, Grynberg, Michael, additional, Pakiz, Maja, additional, Pavlakis, Kitty, additional, Vermeulen, Nathalie, additional, Zannoni, Gianfranco, additional, Zapardiel, Ignacio, additional, and Macklon, Kirsten Louise Tryde, additional
- Published
- 2022
- Full Text
- View/download PDF
4. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma,.
- Author
-
Rodolakis, Alexandros, Scambia, Giovanni, Planchamp, François, Acien, Maribel, Sardo, Attilio Di Spiezio, Farrugia, Martin, Grynberg, Michael, Pakiz, Maja, Pavlakis, Kitty, Vermeulen, Nathalie, Zannoni, Gianfranco, Zapardiel, Ignacio, and Macklon, Kirsten Louise Tryde
- Subjects
TREATMENT of endometrial cancer ,FOLLOW-up studies (Medicine) ,FERTILITY preservation - Abstract
STUDY QUESTION How should fertility-sparing treatment of patients with endometrial carcinoma be performed? SUMMARY ANSWER Forty-eight recommendations were formulated on fertility-sparing treatment of patients with endometrial carcinoma. WHAT IS KNOWN ALREADY The standard surgical treatment of endometrial carcinoma consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in endometrial carcinoma in a multidisciplinary setting. While addressing also work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility-sparing treatment. STUDY DESIGN, SIZE, DURATION A collaboration was set up between the ESGO, the European Society of Human Reproduction and Embryology (ESHRE) and the European Society for Gynaecological Endoscopy (ESGE), aiming to develop clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. PARTICIPANTS/MATERIALS, SETTING, METHODS ESGO/ESHRE/ESGE nominated an international multidisciplinary development group consisting of practising clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (11 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2016, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgement was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 95 independent international practitioners in cancer care delivery and patient representatives. MAIN RESULTS AND THE ROLE OF CHANCE The multidisciplinary development group formulated 48 recommendations in four sections; patient selection, tumour clinicopathological characteristics, treatment and special issues. LIMITATIONS, REASONS FOR CAUTION Of the 48 recommendations, none could be based on level I evidence and only 16 could be based on level II evidence, implicating that 66% of the recommendations are supported only by observational data, professional experience and consensus of the development group. WIDER IMPLICATIONS OF THE FINDINGS These recommendations provide guidance to professionals caring for women with endometrial carcinoma, including but not limited to professionals in the field of gynaecological oncology, onco-fertility, reproductive surgery, endoscopy, conservative surgery and histopathology, and will help towards a holistic and multidisciplinary approach for this challenging clinical scenario. STUDY FUNDING/COMPETING INTEREST(S) All costs relating to the development process were covered from ESGO, ESHRE and ESGE funds. There was no external funding of the development process or manuscript production. G.S. has reported grants from MSD Italia S.r.l. advisory boards for Storz, Bayer, Astrazeneca, Metronic, TESARO Bio Italy S.r.l and Johnson & Johnson, and honoraria for lectures from Clovis Oncology Italy S.r.l. M.G. has reported advisory boards for Gedeon Richter and Merck. The other authors have reported no conflicts of interest. DISCLAIMER This document represents the views of ESHRE, ESGO and ESGE which are the result of consensus between the relevant stakeholders and where relevant based on the scientific evidence available at the time of preparation. The recommendations should be used for informational and educational purposes. They should not be interpreted as setting a standard of care, or be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgement to each individual presentation, nor variations based on locality and facility type. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial
- Author
-
Cibula, David, Kocian, Roman, Plaikner, Andrea, Jarkovsky, Jiri, Klat, Jaroslav, Zapardiel, Ignacio, Pilka, Radovan, Torné Bladé, Aureli, Sehnal, Borek, Ostojich, Borek, Petiz, Almerinda, Sanchez, Octavio A., Presl, Jiri, Buda, Alessandro, Raspagliesi, Francesco, Kascak, Peter, van Lonkhuijzen, Luc, Barahona, Marc, Minar, Lubos, Blecharz, Pawel, Pakiz, Maja, Wydra, Dariusz, Snyman, Leon C., Zalewski, Kamil, Zorrero, Cristina, Havelka, Pavel, Redecha, Mikulas, Vinnytska, Alla, Vergote, Ignace, Tingulstad, Solveig, Michal, Martin, Kipp, Barbara, Slama, Jiri, Marnitz, Simone, Bajsova, Sylvia, Hernández, Alicia, Fischerova, Daniela, Nemejcova, Kristyna, Kohler, Christhardt, and Obstetrics and Gynaecology
- Subjects
Adult ,Càncer de coll uterí ,Frozen section ,INDOCYANINE GREEN ,SLN ,Uterine Cervical Neoplasms ,Metastasis ,Metàstasi ,Humans ,Prospective Studies ,FALSE-NEGATIVE RATE ,Aged ,Science & Technology ,Sentinel Lymph Node Biopsy ,ENDOMETRIAL ,WOMEN ,Middle Aged ,LYMPHADENECTOMY ,Micrometastases ,Oncology ,Mapping ,RISK-FACTORS ,BIOPSY ,Cervical cancer ,HYSTERECTOMY ,Female ,RADIOTRACER ,Ultrastaging ,Sentinel Lymph Node ,Life Sciences & Biomedicine ,Sentinel lymph node - Abstract
BACKGROUND: SENTIX (ENGOT-CX2/CEEGOG-CX1) is an international, multicentre, prospective observational trial evaluating sentinel lymph node (SLN) biopsy without pelvic lymph node dissection in patients with early-stage cervical cancer. We report the final preplanned analysis of the secondary end-points: SLN mapping and outcomes of intraoperative SLN pathology. METHODS: Forty-seven sites (18 countries) with experience of SLN biopsy participated in SENTIX. We preregistered patients with stage IA1/lymphovascular space invasion-positive to IB2 (4 cm or smaller or 2 cm or smaller for fertility-sparing treatment) cervical cancer without suspicious lymph nodes on imaging before surgery. SLN frozen section assessment and pathological ultrastaging were mandatory. Patients were registered postoperatively if SLN were bilaterally detected in the pelvis, and frozen sections were negative. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02494063). RESULTS: We analysed data for 395 preregistered patients. Bilateral detection was achieved in 91% (355/395), and it was unaffected by tumour size, tumour stage or body mass index, but it was lower in older patients, in patients who underwent open surgery, and in sites with fewer cases. No SLN were found outside the seven anatomical pelvic regions. Most SLN and positive SLN were localised below the common iliac artery bifurcation. Single positive SLN above the iliac bifurcation were found in 2% of cases. Frozen sections failed to detect 54% of positive lymph nodes (pN1), including 28% of cases with macrometastases and 90% with micrometastases. INTERPRETATION: SLN biopsy can achieve high bilateral SLN detection in patients with tumours of 4 cm or smaller. At experienced centres, all SLN were found in the pelvis, and most were located below the iliac vessel bifurcation. SLN frozen section assessment is an unreliable tool for intraoperative triage because it only detects about half of N1 cases. ispartof: EUROPEAN JOURNAL OF CANCER vol:137 pages:69-80 ispartof: location:England status: published
- Published
- 2020
6. Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)
- Author
-
Nemejcova, Kristyna, Kocian, Roman, Kohler, Christhardt, Jarkovsky, Jiri, Klat, Jaroslav, Berjon, Alberto, Pilka, Radovan, Sehnal, Borek, Gil-Ibanez, Blanca, Lupo, Ezequiel, Petiz, Almerinda, Arencibia Sanchez, Octavio, Kascak, Peter, Martinelli, Fabio, Buda, Alessandro, Presl, Jiri, Barahona, Marc, van Lonkhuijzen, Luc, Szatkowski, Wiktor, Minar, Lubos, Pakiz, Maja, Havelka, Pavel, Zorrero, Cristina, Misiek, Marcin, Snyman, Leon Cornelius, Wydra, Dariusz, Vergote, Ignace, Vinnytska, Alla, Redecha, Mikulas, Michal, Martin, Tingulstad, Solveig, Kipp, Barbara, Szewczyk, Grzegorz, Toth, Robert, de Santiago Garcia, Francisco Javier, Coronado Martin, Pluvio Jesus, Poka, Robert, Tamussino, Karl, Luyckx, Mathieu, Fastrez, Maxime, Carlos Staringer, Juan, Germanova, Anna, Plaikner, Andrea, Bajsova, Sylva, Dundr, Pavel, Mallmann-Gottschalk, Nina, Cibula, David, Nemejcova, Kristyna, Kocian, Roman, Kohler, Christhardt, Jarkovsky, Jiri, Klat, Jaroslav, Berjon, Alberto, Pilka, Radovan, Sehnal, Borek, Gil-Ibanez, Blanca, Lupo, Ezequiel, Petiz, Almerinda, Arencibia Sanchez, Octavio, Kascak, Peter, Martinelli, Fabio, Buda, Alessandro, Presl, Jiri, Barahona, Marc, van Lonkhuijzen, Luc, Szatkowski, Wiktor, Minar, Lubos, Pakiz, Maja, Havelka, Pavel, Zorrero, Cristina, Misiek, Marcin, Snyman, Leon Cornelius, Wydra, Dariusz, Vergote, Ignace, Vinnytska, Alla, Redecha, Mikulas, Michal, Martin, Tingulstad, Solveig, Kipp, Barbara, Szewczyk, Grzegorz, Toth, Robert, de Santiago Garcia, Francisco Javier, Coronado Martin, Pluvio Jesus, Poka, Robert, Tamussino, Karl, Luyckx, Mathieu, Fastrez, Maxime, Carlos Staringer, Juan, Germanova, Anna, Plaikner, Andrea, Bajsova, Sylva, Dundr, Pavel, Mallmann-Gottschalk, Nina, and Cibula, David
- Abstract
The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.
- Published
- 2020
7. Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)
- Author
-
Nemejcova, Kristyna, primary, Kocian, Roman, additional, Kohler, Christhardt, additional, Jarkovsky, Jiri, additional, Klat, Jaroslav, additional, Berjon, Alberto, additional, Pilka, Radovan, additional, Sehnal, Borek, additional, Gil-Ibanez, Blanca, additional, Lupo, Ezequiel, additional, Petiz, Almerinda, additional, Arencibia Sanchez, Octavio, additional, Kascak, Peter, additional, Martinelli, Fabio, additional, Buda, Alessandro, additional, Presl, Jiri, additional, Barahona, Marc, additional, van Lonkhuijzen, Luc, additional, Szatkowski, Wiktor, additional, Minar, Lubos, additional, Pakiz, Maja, additional, Havelka, Pavel, additional, Zorrero, Cristina, additional, Misiek, Marcin, additional, Snyman, Leon Cornelius, additional, Wydra, Dariusz, additional, Vergote, Ignace, additional, Vinnytska, Alla, additional, Redecha, Mikulas, additional, Michal, Martin, additional, Tingulstad, Solveig, additional, Kipp, Barbara, additional, Szewczyk, Grzegorz, additional, Toth, Robert, additional, de Santiago Garcia, Francisco Javier, additional, Coronado Martin, Pluvio Jesus, additional, Poka, Robert, additional, Tamussino, Karl, additional, Luyckx, Mathieu, additional, Fastrez, Maxime, additional, Staringer, Juan Carlos, additional, Germanova, Anna, additional, Plaikner, Andrea, additional, Bajsova, Sylva, additional, Dundr, Pavel, additional, Mallmann-Gottschalk, Nina, additional, and Cibula, David, additional
- Published
- 2020
- Full Text
- View/download PDF
8. Incidence of positive peritoneal cytology in patients with endometrial carcinoma after hysteroscopy vs. dilatation and curettage.
- Author
-
Dovnik, Andraz, Crnobrnja, Bojana, Zegura, Branka, Pakiz, Maja, and Takac, Iztok
- Subjects
CHI-squared test ,CYTOLOGY ,HYSTEROSCOPY ,ENDOMETRIAL tumors ,DISEASE incidence ,DESCRIPTIVE statistics ,DILATATION & curettage - Abstract
The article focuses on patients with endometrial cancer and mentions hysteroscopy (HSC) and dilatation and curettage (D&C). Topics discussed include positive peritoneal cytology, diagnosis of endometrial cancer and endometrial biopsy. Other topics which includes peritoneal washings are also discussed.
- Published
- 2017
- Full Text
- View/download PDF
9. Solitary and multiple uterine leiomyomas among Caucasian women: two different disorders?
- Author
-
Pakiz, Maja, primary, Potocnik, Uros, additional, and But, Igor, additional
- Published
- 2010
- Full Text
- View/download PDF
10. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma .
- Author
-
Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M, Grynberg M, Pakiz M, Pavlakis K, Vermeulen N, Zannoni G, Zapardiel I, and Macklon KLT
- Abstract
Study Question: How should fertility-sparing treatment of patients with endometrial carcinoma be performed?, Summary Answer: Forty-eight recommendations were formulated on fertility-sparing treatment of patients with endometrial carcinoma., What Is Known Already: The standard surgical treatment of endometrial carcinoma consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in endometrial carcinoma in a multidisciplinary setting. While addressing also work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility-sparing treatment., Study Design Size Duration: A collaboration was set up between the ESGO, the European Society of Human Reproduction and Embryology (ESHRE) and the European Society for Gynaecological Endoscopy (ESGE), aiming to develop clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide., Participants/materials Setting Methods: ESGO/ESHRE/ESGE nominated an international multidisciplinary development group consisting of practising clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (11 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2016, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgement was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 95 independent international practitioners in cancer care delivery and patient representatives., Main Results and the Role of Chance: The multidisciplinary development group formulated 48 recommendations in four sections; patient selection, tumour clinicopathological characteristics, treatment and special issues., Limitations Reasons for Caution: Of the 48 recommendations, none could be based on level I evidence and only 16 could be based on level II evidence, implicating that 66% of the recommendations are supported only by observational data, professional experience and consensus of the development group., Wider Implications of the Findings: These recommendations provide guidance to professionals caring for women with endometrial carcinoma, including but not limited to professionals in the field of gynaecological oncology, onco-fertility, reproductive surgery, endoscopy, conservative surgery and histopathology, and will help towards a holistic and multidisciplinary approach for this challenging clinical scenario., Study Funding/competing Interests: All costs relating to the development process were covered from ESGO, ESHRE and ESGE funds. There was no external funding of the development process or manuscript production. G.S. has reported grants from MSD Italia S.r.l., advisory boards for Storz, Bayer, Astrazeneca, Metronic, TESARO Bio Italy S.r.l and Johnson & Johnson, and honoraria for lectures from Clovis Oncology Italy S.r.l. M.G. has reported advisory boards for Gedeon Richter and Merck. The other authors have reported no conflicts of interest., Disclaimer: This document represents the views of ESHRE, ESGO and ESGE which are the result of consensus between the relevant stakeholders and where relevant based on the scientific evidence available at the time of preparation . The recommendations should be used for informational and educational purposes. They should not be interpreted as setting a standard of care, or be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgement to each individual presentation, nor variations based on locality and facility type ., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.